IFG Advisors LLC Acquires 7,700 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

IFG Advisors LLC lifted its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 41.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 26,400 shares of the company’s stock after acquiring an additional 7,700 shares during the quarter. IFG Advisors LLC owned approximately 0.06% of Zevra Therapeutics worth $183,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Sanctuary Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at approximately $474,000. Vanguard Group Inc. boosted its stake in shares of Zevra Therapeutics by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after acquiring an additional 58,866 shares during the period. Retirement Planning Co of New England Inc. boosted its position in Zevra Therapeutics by 11.0% during the first quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock worth $2,495,000 after purchasing an additional 42,766 shares during the period. Mystic Asset Management Inc. raised its position in shares of Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock valued at $1,545,000 after purchasing an additional 35,514 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics during the 4th quarter worth about $177,000. 35.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZVRA has been the topic of several research analyst reports. JMP Securities assumed coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. Roth Mkm increased their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, September 18th. Finally, William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.83.

Zevra Therapeutics Trading Down 0.5 %

Shares of Zevra Therapeutics stock opened at $8.49 on Friday. The firm’s 50-day moving average price is $7.54 and its two-hundred day moving average price is $5.97. The company has a market capitalization of $355.33 million, a price-to-earnings ratio of -6.29 and a beta of 1.94. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. Zevra Therapeutics, Inc. has a 12-month low of $3.89 and a 12-month high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The business had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same quarter in the previous year, the company earned ($0.15) earnings per share. On average, analysts forecast that Zevra Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.